Crossmark

Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer

Crossref DOI link: https://doi.org/10.1038/s41523-023-00542-1

Published Online: 2023-05-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Ziyan https://orcid.org/0000-0002-5390-1991
Feng, Jianguo

Jing, Ji https://orcid.org/0000-0003-1004-8377
Huang, Yuan

Ye, Wei-Wu

Lei, Lei https://orcid.org/0000-0002-6838-4050
Wang, Xiao-Jia https://orcid.org/0000-0002-7005-0842
Cao, Wen-Ming https://orcid.org/0000-0002-5644-3156
Funding

Funding for this research was provided by:

Natural Science Foundation of Zhejiang Province (LY21H160005)

Zhejiang Province Public Welfare Technology Application Research Project (2019C04001 and 2020C04012)
License Information

Text and Data Mining valid from 2023-05-09

Version of Record valid from 2023-05-09
More Information

Article History

Received: 30 November 2021

Accepted: 18 April 2023

First Online: 9 May 2023

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below